120
Participants
Start Date
November 25, 2022
Primary Completion Date
March 31, 2025
Study Completion Date
July 31, 2030
Patritumab deruxtecan
HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
Chemotherapy
Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
Letrozole
Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
Complejo Hospitalario San Pedro de Alcántara, Cáceres
Hospital Universitario Reina Sofia, Córdoba
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
Hospital Universitario Virgen de las Nieves, Granada
Hospital Universitario Puerta de Hierro de Majadahonda, Madrid
Hospital Universitario Rey Juan Carlos, Móstoles
Hospital Universitario Virgen de la Arrixaca, Murcia
Hospital Universitario de Canarias, Santa Cruz de Tenerife
Hospital Sant Joan de Reus, Reus
ICO Badalona, Badalona
Hospital Universitario de Fuenlabrada, Fuenlabrada
Hospital General de Catalunya, Barcelona
Hospital Universitari Vall d' Hebrón, Barcelona
Hospital de Basurto, Bilbao
H.Univ. Arnau de Vilanova de Lleida, Lleida
Hospital Universitario 12 de Octubre, Madrid
HAU de Manresa, Manresa
Hospital Son Espases, Palma de Mallorca
HU Parc Tauli, Sabadell
Comp. Hosp.Univ. Santiago (Chus), Santiago de Compostela
Hospital Universitario Virgen del Rocio, Seville
H La Fe, Valencia
Hospital Clínico de Valencia, Valencia
Hospital Universitario de Badajoz, Badajoz
Hospital Clinic de Barcelona, Barcelona
Collaborators (1)
Daiichi Sankyo
INDUSTRY
SOLTI Breast Cancer Research Group
OTHER